AR070534A1 - Agonistas de receptores muscarinicos - Google Patents
Agonistas de receptores muscarinicosInfo
- Publication number
- AR070534A1 AR070534A1 ARP090100687A ARP090100687A AR070534A1 AR 070534 A1 AR070534 A1 AR 070534A1 AR P090100687 A ARP090100687 A AR P090100687A AR P090100687 A ARP090100687 A AR P090100687A AR 070534 A1 AR070534 A1 AR 070534A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- heteroaryl
- cycloalkyl
- independently
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- -1 C3- heteroaryl 5 Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 abstract 1
- SAESQDQEKFIXQO-YKSBVNFPSA-N (4as,8as)-1-[1-[1-(2-methylbenzoyl)piperidin-4-yl]piperidin-4-yl]-4a,5,6,7,8,8a-hexahydro-4h-benzo[d][1,3]oxazin-2-one Chemical compound CC1=CC=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(OC[C@H]3CCCC[C@@H]32)=O)CC1 SAESQDQEKFIXQO-YKSBVNFPSA-N 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XQEPLYLEYBCDLB-UHFFFAOYSA-N propan-2-yl pyrrolidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCCC1 XQEPLYLEYBCDLB-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas que incluyen los compuestos proceso e intermediario. Son utiles en terapia, en particular en el tratamiento del dolor, alzheimer y esquizofrenia. Reivindicacion 1: Un compuesto de Formula 1: o una sal farmacéuticamente aceptable del mismo; en la que: Y es -CR3R4-, -NR5-, -O-, o -S-; X es -CR6R7-, -NR8-, -O-, o -S-; con la condicion de que Y sea -CR3R4- o X sea -CR6R7-; cada A es, independientemente, alquilo de C1-3, o dos A están enlazados juntos para formar un puente de alquileno de C1-3; R1 es hidrogeno, alquilo de C1-6, o haloalquilo de C1-6; R2 es -C(O)ORa, -C(O)Rb, -C(O)NRcRd, alquilo de C1-6, haloalquilo de C1-6, cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, heterocicloalquil C3-7-alquilo de C1-3, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, o heteroaril C3-9alquilo de C1-3 en el que los anillos de dichos arilo C6-10 aril de C6-10-alquilo de C1-3, heteroarilo de C3-9, y heteroaril C3-9-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos seleccionados independientemente; en el que los anillos de dichos cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, y heterocicloalquil C3-7-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R10 seleccionados independientemente; y en el que dichos alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, alcoxi de C1-6, y haloalcoxi de C1-6 están cada uno opcionalmente sustituidos con 1, 2 o 3 grupos R11 seleccionados independientemente: R3, R4, R6, y R7 son cada uno, independientemente, hidrogeno, fluoro, alquilo de C1-4, alcoxi de C1-4-metilo, ciano-alquilo de C1-4 o haloalquilo de C1-4; R5 y R8 son cada uno, independientemente, hidrogeno, alquilo de C1-4, o haloalquilo de C1-4: cada R9 y R10 es, independientemente, fenilo, cicloalquilo de C3-6, heterocicloalquilo de C2-5 , heteroarilo de C3-5, -CN, -SRe, -ORe, O(CH2)r-ORe, Re, -C(O)-Re, -CO2Re, -SO2Re, -SO2NReRf, halogeno, -NO2, NReRf, -(CH2)rNReRf, o -C(O)NReRf: cada R11 es, independientemente, -CN, -NO2, ORe, o NReRf; Ra, Rb, Rc, y Rd son cada uno, independientemente, hidrogeno, alquilo de C1-7, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, cicloalquilo de C3-7, cicloalquil C3-7 alquilo de C1-3, heterocicloalquilo de C3-7, heterocicloalquil C3-7-alquilo de C1-3, arilo de C6-10, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, o heteroaril C3-9-alquilo de C1-3: en los que los anillos de dichos arilo de C6-10, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, y heteroaril C3-9-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R12 seleccionados independientemente; en los que los anillos de dichos cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, y heterocicloalquil C3-7-alquilo de C1-3, están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R13 seleccionados independientemente: y en los que dicho alquilo de C1-7, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, alcoxi de C1-7, y haloalcoxi de C1-6 están cada uno opcionalmente sustituidos con 1, 2 o 3 grupos R14 seleccionados independientemente: cada R12, R13, y R14 es, independientemente, fenilo, cicloalquilo de C3-6, heterocicloalquilo de C2-5, heteroarilo de C3-5, -CN, -SRg, -ORg, -O(CH2)r-ORg, Rg, -C(O)-Rg, -CO2Rg, -SO2Rg, -SO2NRgRh, halogeno, -NO2, -NRgRh, -(CH2)NRgRh, o -C(O)-NRgRh: cada Re, Rf, Rg y Rh es, independientemente, hidrogeno, alquilo de C1-6, alquenilo de C2-6 o haloalquilo de C1-6, m es 1, 2 o 3: p es 0, 1 o 2: q es un numero entero de 0 a [6+(px2)]; y r es 1, 2, 3 o 4; con la condicion de que el compuesto no sea 4'-metil-4-((4aS,8aS)-2-oxooctahidroquinoxalin-1(2H)-il)-1,4'-bipiperidin-1'-carboxilato de isopropilo, 4-[4-[(4aS,8aS)2-oxo-3,4,4a,5,6,7,8,8a-octahidroquinoxalin-1-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de isopropilo, (3S)-3-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-iI]-1-piperidil]pirrolidin-1-carboxilato de isopropilo, 4-[4-[(4aR,8aR)-2-oxo-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-1-il]-1-piperidil]piperidin-1-carboxilato de terc-butilo, 4-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de isopropilo, (4aS,8aS)-1-[1-[1-(2-metilbenzoil)-4-piperidil]-4-piperidil]-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-2-ona, 4-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-il]-1-piperidil]piperidin-1-carboxilato de terc-butilo, 4-[4-[(4aS,8aS)-2-oxo-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-1-il]-1-piperidil]piperidin-1-carboxilato de metilo, o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3213808P | 2008-02-28 | 2008-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070534A1 true AR070534A1 (es) | 2010-04-14 |
Family
ID=41013656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100687A AR070534A1 (es) | 2008-02-28 | 2009-02-27 | Agonistas de receptores muscarinicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090221567A1 (es) |
| EP (1) | EP2257543A4 (es) |
| JP (1) | JP2011513302A (es) |
| KR (1) | KR20100131463A (es) |
| CN (1) | CN102015687A (es) |
| AR (1) | AR070534A1 (es) |
| AU (1) | AU2009217823A1 (es) |
| BR (1) | BRPI0907992A2 (es) |
| CA (1) | CA2716855A1 (es) |
| CL (1) | CL2009000445A1 (es) |
| MX (1) | MX2010009395A (es) |
| PE (1) | PE20091433A1 (es) |
| RU (1) | RU2010135253A (es) |
| TW (1) | TW200940522A (es) |
| UY (1) | UY31672A1 (es) |
| WO (1) | WO2009108117A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| CN107098899B (zh) * | 2012-09-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PE20221453A1 (es) | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
| EP4574827A4 (en) * | 2022-10-28 | 2026-01-07 | Neushen Therapeutics Shanghai Co Ltd | Nitrogen heterocyclic compounds and their pharmaceutically acceptable salts, their preparation process and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032481A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7279490B2 (en) * | 2002-06-17 | 2007-10-09 | Merck & Co, Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP5209481B2 (ja) * | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用 |
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
-
2009
- 2009-02-25 UY UY031672A patent/UY31672A1/es unknown
- 2009-02-25 US US12/392,219 patent/US20090221567A1/en not_active Abandoned
- 2009-02-26 TW TW098106217A patent/TW200940522A/zh unknown
- 2009-02-27 MX MX2010009395A patent/MX2010009395A/es not_active Application Discontinuation
- 2009-02-27 RU RU2010135253/04A patent/RU2010135253A/ru unknown
- 2009-02-27 CN CN2009801151241A patent/CN102015687A/zh active Pending
- 2009-02-27 CL CL2009000445A patent/CL2009000445A1/es unknown
- 2009-02-27 BR BRPI0907992A patent/BRPI0907992A2/pt not_active IP Right Cessation
- 2009-02-27 AR ARP090100687A patent/AR070534A1/es unknown
- 2009-02-27 AU AU2009217823A patent/AU2009217823A1/en not_active Abandoned
- 2009-02-27 PE PE2009000314A patent/PE20091433A1/es not_active Application Discontinuation
- 2009-02-27 JP JP2010548644A patent/JP2011513302A/ja active Pending
- 2009-02-27 WO PCT/SE2009/050216 patent/WO2009108117A1/en not_active Ceased
- 2009-02-27 EP EP09715794A patent/EP2257543A4/en not_active Withdrawn
- 2009-02-27 CA CA2716855A patent/CA2716855A1/en not_active Abandoned
- 2009-02-27 KR KR1020107021430A patent/KR20100131463A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2257543A4 (en) | 2012-03-21 |
| WO2009108117A1 (en) | 2009-09-03 |
| KR20100131463A (ko) | 2010-12-15 |
| CN102015687A (zh) | 2011-04-13 |
| TW200940522A (en) | 2009-10-01 |
| UY31672A1 (es) | 2009-09-30 |
| CL2009000445A1 (es) | 2011-05-06 |
| JP2011513302A (ja) | 2011-04-28 |
| MX2010009395A (es) | 2010-09-24 |
| US20090221567A1 (en) | 2009-09-03 |
| AU2009217823A1 (en) | 2009-09-03 |
| BRPI0907992A2 (pt) | 2017-06-13 |
| EP2257543A1 (en) | 2010-12-08 |
| PE20091433A1 (es) | 2009-10-24 |
| CA2716855A1 (en) | 2009-09-03 |
| RU2010135253A (ru) | 2012-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070534A1 (es) | Agonistas de receptores muscarinicos | |
| PE20160240A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20160241A1 (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
| AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
| AR070744A1 (es) | Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion -176 | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| AR087355A1 (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR084515A1 (es) | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |